The Latin America Cell Isolation Market was valued at $83.7 Million in 2026 and projected to reach to $135.3 Million by 2031, representing a compound annual growth rate of 10.1%. Latin America's cell isolation market is positioned for sustained growth as healthcare providers increasingly recognize the value of advanced cell separation technologies in clinical and research applications.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Latin America is witnessing accelerated investments in regenerative medicine and stem cell therapies, driving demand for advanced cell isolation technologies across research institutions and clinical facilities.
Rising adoption of advanced diagnostic technologies in Latin American healthcare systems is propelling the cell isolation market, with hospitals and diagnostic centers upgrading to modern isolation equipment.
Growing demand for personalized medicine approaches across Latin America is creating new opportunities for cell isolation applications in patient-specific treatment protocols and precision healthcare.
The Latin America cell isolation market is projected to grow from $83.7 million in 2026 to $135.3 million by 2031, representing a robust 10.1% CAGR driven by healthcare modernization initiatives.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | SURFACE MARKER-BASED CELL ISOLATION (Technique) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 12.7% from 2026 to 2031 |
| Largest Segment | CONSUMABLES (Product) |
| Market Size Base Year (Billions) | ~USD 4.38 (2026) |
| Revenue Forecast (Billions) | ~USD 7.97 (2031) |
| Segments Covered | Product, Type, Cell Type, Cell Source, Technique |
5 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CEPHEID INC. | United States | Private Company | GeneXpert instruments and Xpert test cartridges,SmartCycler system and reagents,Custom and collaborative programs (USPS BDS, TB, Ebola, new molecular tests), |
| MAXCYTE, INC | United States | Public Company | ExPERT STx and GTx flow electroporation instruments,ExPERT ATx and VLx instruments,Disposable processing assemblies (PAs), |
| GENERAL ELECTRIC | United States | Public Company | Commercial Engines & Services,Defense & Propulsion Technologies, |
| GE HEALTHCARE | United States | Public Company | Imaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS), |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and single-use),Life Sciences tools and genomics,Diagnostics, |
| MERCK KGAA | Germany | Public Company | Life Science (reagents, consumables, bioprocessing, CDMO/testing),Healthcare (oncology, neurology, fertility, rare diseases, cardiovascular, metabolic),Electronics (semiconductor and display materials, specialty gases, delivery equipment), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| BECTON, DICKINSON AND COMPANY | United States | Public Company | Medical Essentials (syringes, needles, catheters, sharps, vascular care),Connected Care (infusion, dispensing, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery, pharma solutions), |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| SARTORIUS AG | Germany | Public Company | Bioprocess solutions (bioreactors, cell culture, fluid management, process filtration),Analytical instruments and process analytics,Lab products and services (filtration, water systems, weighing, pipettes, microbiological testing), |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Research and Bioprocess, |
| QIAGEN | Netherlands | Public Company | Sample technologies (nucleic acid purification & stabilization),Molecular diagnostics assays (immune response, oncology, SRH, viral load),PCR & dPCR instruments and reagents, |
| REVVITY | United States | Public Company | Diagnostics instruments and automation platforms,Diagnostics reagents, assays, and kits,Life science research tools and genomic workflow solutions, |
| CORNING INCORPORATED | United States | Public Company | Optical Communications (fiber, cable, hardware, components),Display Glass Substrates (LCD, OLED),Specialty Materials (mobile, semiconductor optics, defense, radiation shielding, sunglasses), |
| LONZA | Switzerland | Public Company | Integrated Biologics (mammalian and drug product platforms),Advanced Synthesis (small molecules, HPAPIs, ADCs and bioconjugates),Specialized Modalities (cell & gene, microbial, bioscience, mRNA), |
| BIO-TECHNE | United States | Public Company | Protein Sciences (reagents and proteomic tools),Diagnostics (controls, calibrators, assays, process controls),Spatial Biology and Genomics, |
| TERUMO CORPORATION | Japan | Public Company | Cardiac and Vascular Company,Medical Care Solutions Company,Blood and Cell Technologies Company, |
Cepheid Inc. is a United States-based private company founded in 1996 with 1,700 employees. The company develops molecular diagnostics and point-of-care testing solutions.
MaxCyte, Inc. is a publicly traded United States company founded in 1998 with 91 employees. The company develops cell engineering technologies and platforms.
General Electric is a publicly traded United States conglomerate founded in 1892 with 57,000 employees. The company operates across multiple industrial and technology sectors.
GE Healthcare is a publicly traded United States company established in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.
Danaher Corporation is a publicly traded United States company founded in 1969 with 59,000 employees. The company operates a diversified portfolio of businesses in life sciences, diagnostics, and environmental solutions.
Merck KGaA is a publicly traded German company founded in 1668 with 59,077 employees. The company operates in pharmaceuticals, life sciences, and performance materials.
Thermo Fisher Scientific Inc. is a publicly traded United States company founded in 1956 with 125,000 employees. The company provides laboratory equipment, reagents, and services for research and diagnostics.
Becton, Dickinson and Company is a publicly traded United States company founded in 1897 with 72,000 employees. The company manufactures medical devices, laboratory equipment, and diagnostic products.
Agilent Technologies, Inc. is a publicly traded United States company founded in 1999 with 18,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.
Sartorius AG is a publicly traded German company founded in 1870 with 14,242 employees. The company manufactures laboratory and bioprocess equipment for pharmaceutical and biotechnology industries.
Bio-Rad Laboratories, Inc. is a publicly traded United States company founded in 1952 with 7,450 employees. The company develops and manufactures life science research and clinical diagnostics products.
QIAGEN is a publicly traded Netherlands-based company founded in 1984 with 5,500 employees. The company provides molecular diagnostics, sample preparation, and bioinformatics solutions.
Revvity is a publicly traded United States company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for life sciences research and diagnostics.
Corning Incorporated is a publicly traded United States company founded in 1851 with 67,200 employees. The company manufactures specialty glass, ceramics, and laboratory products.
Lonza is a publicly traded Swiss company founded in 1897 with 20,000 employees. The company provides contract manufacturing and life science solutions for pharmaceuticals and biotechnology.
Bio-Techne is a publicly traded United States company founded in 1976 with 3,100 employees. The company develops and manufactures proteins, antibodies, and reagents for life sciences research.
Terumo Corporation is a publicly traded Japanese company founded in 1921 with 30,591 employees. The company manufactures medical devices and blood management solutions.
| Country | 2025 size (native) |
|---|---|
| Brazil | USD 67.4 Million |
| Mexico | USD 36.7 Million |
| Rest Of Latin America | USD 31.3 Million |
The Latin America cell isolation market was valued at $83.7 million in 2026 and is projected to grow to $135.3 million by 2031.
Latin America's cell isolation market is expected to grow at a compound annual growth rate (CAGR) of 10.1% from 2026 to 2031.
Key drivers include increasing investments in regenerative medicine, rising adoption of advanced diagnostic technologies, growing demand for personalized medicine, and improved healthcare infrastructure across Latin America.
Latin America offers cost-effective manufacturing, favorable regulatory environments, and strong academic-private sector collaboration, making it attractive for cell therapy development and international investment.
Regenerative medicine, cell-based diagnostics, personalized medicine, and clinical cell therapy applications are the most prominent segments driving demand in Latin America.
This research study extensively used secondary sources, directories, and databases to identify and collect information for analysis of the global cell isolation market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with primary research inputs to determine the final market size.
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the cell isolation market. The secondary sources used for this study include World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Stem Cell Society Singapore (SCSS), International Society for Advancement of Cytometry (ISAC), American Filtration and Separations Society (AFS), Food and Drug Administration (FDA), American Society for Cell Biology (ASC8), National Institutes of Health (NIH), International Society for Cell & Gene Therapy (ISCT), American Society for Gene and Cell Therapy (ASGCT), Pharmaceutical Research and Manufacturers of America (PhRMA), Japan Agency for Medical Research and Development, European Federation of Pharmaceutical Industries and Associations (EFPIA), and the Alliance for Regenerative Medicine (ARM). Secondary data were collected and analyzed to determine the overall size of the global cell isolation market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
The top-down and bottom-up approaches were used to estimate & validate the total size of the cell isolation market. These methods were also used extensively to estimate the size of various market segments.

After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Cell isolation is the process of separating specific cells from a given sample. It is a tool in biological research that enables the isolation of a single cell type from heterogeneous cell populations without contamination by other cell types. This process is widely used for the isolation of biomolecules to produce vaccines, drugs, antibodies, enzymes, proteins, and other biotechnology products.
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:
Full forecast, segment splits, and company analysis for all Cell Isolation Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report